Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05958017 · ClinicalTrials.gov registry record · NA
reSET for the Treatment of Stimulant Use in HIV Clinics: Care Optimization Supporting Treatment Adherence (COSTA)
A NA study of Stimulant Use Disorder and People Living With HIV, sponsored by University of Miami.
- Recruiting
- Registry status
- NA
- Development phase
- 500
- Enrollment target
- 1
- Study location
NCT05958017: Recruiting NA study of Stimulant Use Disorder and People Living With HIV, sponsored by University of Miami.
NCT05958017 is a NA study of Stimulant Use Disorder and People Living With HIV that is actively recruiting participants, run by University of Miami. The registered enrollment target is 500 participants, above the 155-participant average among 9 other Stimulant Use Disorder trials with a reported enrollment target (223% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05958017, a NA study of Stimulant Use Disorder and People Living With HIV, is actively recruiting participants, sponsored by University of Miami.
- RECRUITING
- Registry status
- NA
- Development phase
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find out if reSET, an FDA authorized mobile therapeutic, is effective in treating stimulant use disorder and helping keep HIV viral load suppression stable among men who have sex with men who are living with HIV and have a stimulant use disorder.
Primary Outcome
Number of days of stimulant use as measured by the Timeline FollowBack using the formula: Daily opioid use- the proportion of days of use
Conditions Studied
Interventions
- BEHAVIORAL reSET
- OTHER Standard of care
Study Locations (1)
Florida
- University of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2025-03-04 |
| Est. Completion | 2028-01-31 |
| Phase | NA |
What NCT05958017 shows while recruiting
NCT05958017 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 155-participant average among 9 other Stimulant Use Disorder trials with a reported enrollment target (223% higher).
The record links to 3 conditions, with Stimulant Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which reSET is the first listed.
NCT05958017 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT05958017 about?
NCT05958017 is a clinical study titled "reSET for the Treatment of Stimulant Use in HIV Clinics: Care Optimization Supporting Treatment Adherence (COSTA)". The purpose of this study is to find out if reSET, an FDA authorized mobile therapeutic, is effective in treating stimulant use disorder and helping keep HIV viral load suppression stable among men who have sex with men who are living with HIV and have a stimulant use disorder.
What is the current status of trial NCT05958017?
This trial is currently recruiting. It is a NA study. The enrollment target is 500 participants. The study started on 2025-03-04. Estimated completion is 2028-01-31.
What conditions does trial NCT05958017 study?
This clinical trial studies the following conditions: Stimulant Use Disorder, People Living With HIV, reSET.
What interventions are being tested in trial NCT05958017?
The interventions under investigation include: reSET (BEHAVIORAL), Standard of care (OTHER).
Who is sponsoring clinical trial NCT05958017?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05958017 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stimulant Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05958017's enrollment target sits among peer trials
500 2nd of 9 the highest of 9 other Stimulant Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stimulant Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Continuum of Care in Hospitalized Patients With Opioid/Stimulant Use Disorder and Infectious Complications From Drug Use
RECRUITING · NA
-
Smartphone Services for Stimulant Use Disorder
RECRUITING · NA
-
Addressing Risk Through Community Treatment for Infectious Disease and Opioid Use Disorder Now (ACTION) Among Justice-involved Populations
ACTIVE NOT RECRUITING · NA
-
Contingency Management for Opioid and Stimulant Use Disorders in Primary Care
ACTIVE NOT RECRUITING · NA
-
Orexin Receptor Antagonism and Sleep in Stimulant Use Disorder
RECRUITING · Phase 2
-
Optimizing Transcranial Magnetic Stimulation for Stimulant Use Disorder
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI